Upcoming Webinar on Viekira Pak - Clinical Care Options
OldenSlow said
Jan 5, 2015
pl1952 wrote:
I posted Wayne's link and the info he provided in another hep c forum because I thought it would provide great information to those who may be interested, and they removed it and I was sent an email that they considered it a "solicitation". LOL I thought that was pretty funny! :)
That's a hoot. It must take all of 30 seconds to verify that CCO is legit. Guess they couldn't be bothered.
pl1952 said
Jan 5, 2015
I posted Wayne's link and the info he provided in another hep c forum because I thought it would provide great information to those who may be interested, and they removed it and I was sent an email that they considered it a "solicitation". LOL I thought that was pretty funny! :)
-- Edited by pl1952 on Tuesday 6th of January 2015 01:14:29 AM
Rubye said
Jan 4, 2015
Thanks for the link.
I've watched their webinars before and listened to Dr. Jacobson previously. I've gotten info from these sources that I've not heard elsewhere. I'm watching.
pl1952 said
Jan 4, 2015
You rock Wayne! This is perfect for me. He's one of the leading liver doctors in NYC. Curious to see what he says about Abbvie's Viekira Pak...just what I've been looking for. Thank you -- I just registered...
-- Edited by pl1952 on Sunday 4th of January 2015 08:17:00 PM
OldenSlow said
Jan 2, 2015
Registration required, but it is straightforward and free. Questions can be submitted during registration process:
Join us for the first in a series of Webinars addressing important developments in HCV care.
The first Webinar will explore the impact of the December 19 US FDA approval of an additional all-oral regimen, paritaprevir/ritonavir/ombitasvir and dasabuvir, for the treatment of chronic genotype 1 HCV infection. In this live, 30-minute CME-certified Webinar, Dr. Ira Jacobson will present details and perspectives on how to incorporate the latest all-oral HCV therapy into clinical practice.
Attendees are invited to participate in the discussion by submitting questions for the expert faculty in advance. CCO will collect questions from attendees during the registration process.
Tuesday, January 6, 2015
2:30 PM - Live Webinar
Details to log in to the Webinar will be sent to the email address you provide during registration.
Agenda
2:30 - 2:45 PM Presentation
Regimen Components, Dosing, and Duration
Key Efficacy and Safety Data Leading to the Approval
That's a hoot. It must take all of 30 seconds to verify that CCO is legit. Guess they couldn't be bothered.
I posted Wayne's link and the info he provided in another hep c forum because I thought it would provide great information to those who may be interested, and they removed it and I was sent an email that they considered it a "solicitation". LOL I thought that was pretty funny! :)
-- Edited by pl1952 on Tuesday 6th of January 2015 01:14:29 AM
Thanks for the link.
I've watched their webinars before and listened to Dr. Jacobson previously. I've gotten info from these sources that I've not heard elsewhere. I'm watching.
You rock Wayne! This is perfect for me. He's one of the leading liver doctors in NYC. Curious to see what he says about Abbvie's Viekira Pak...just what I've been looking for. Thank you -- I just registered...
-- Edited by pl1952 on Sunday 4th of January 2015 08:17:00 PM
Registration required, but it is straightforward and free. Questions can be submitted during registration process:
https://www.regonline.com/register/checkin.aspx?EventId=1661952&MethodId=0&EventSessionId=&startnewreg=1
---------------------------------------------------------
CME-Certified Webinar
Tuesday, January 6, 2015 - 2:30 PM EST
Ira M. Jacobson, MD
Join us for the first in a series of Webinars addressing important developments in HCV care.
The first Webinar will explore the impact of the December 19 US FDA approval of an additional all-oral regimen, paritaprevir/ritonavir/ombitasvir and dasabuvir, for the treatment of chronic genotype 1 HCV infection. In this live, 30-minute CME-certified Webinar, Dr. Ira Jacobson will present details and perspectives on how to incorporate the latest all-oral HCV therapy into clinical practice.
Attendees are invited to participate in the discussion by submitting questions for the expert faculty in advance. CCO will collect questions from attendees during the registration process.
Tuesday, January 6, 2015
2:30 PM - Live Webinar
Details to log in to the Webinar will be sent to the email address you provide during registration.
Agenda
2:30 - 2:45 PM Presentation
Regimen Components, Dosing, and Duration
Key Efficacy and Safety Data Leading to the Approval
Integration Into Clinical Practice
2:45 - 3:00 PM Question-and-Answer Session